{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:23:26Z","timestamp":1793993006638,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005247","name":"University of British Columbia","doi-asserted-by":"publisher","award":["DRG03597"],"award-info":[{"award-number":["DRG03597"]}],"id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014823","name":"VGH and UBC Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ygyno.2025.11.009","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T08:14:07Z","timestamp":1763799247000},"page":"63-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Exploring novel therapeutic targets in vulvar squamous cell carcinoma"],"prefix":"10.1016","volume":"204","author":[{"given":"Madeline","family":"Rhind","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadijah","family":"Abdulhaleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars-Christian","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lien","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Drew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ygyno.2025.11.009_bb0005","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1002\/ijc.34655","article-title":"Global incidence, risk factors and trends of vulvar cancer: a country-based analysis of cancer registries","volume":"153","author":"Huang","year":"2023","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.009_bb0010","doi-asserted-by":"crossref","first-page":"117","DOI":"10.6004\/jnccn.2024.0013","article-title":"Vulvar Cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Abu-Rustum","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.009_bb0015","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/cancers17020186","article-title":"Management of Patients with vulvar cancers: a systematic comparison of international guidelines (NCCN\u2013ASCO\u2013ESGO\u2013BGCS\u2013IGCS\u2013FIGO\u2013French guidelines\u2013RCOG)","volume":"17","author":"Restaino","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ygyno.2025.11.009_bb0020","first-page":"195","article-title":"Overall survival associated with surgery, radiotherapy, and chemotherapy in metastatic vulvar cancer: a retrospective cohort study based on the SEER database","volume":"2","author":"Meng","year":"2023","journal-title":"Cancer Path Ther."},{"issue":"7","key":"10.1016\/j.ygyno.2025.11.009_bb0025","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00432-020-03226-6","article-title":"Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies","volume":"146","author":"Mantovani","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.009_bb0030","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ygyno.2020.01.029","article-title":"Trends in HPV-dependent and HPV-independent vulvar cancers: the changing face of vulvar squamous cell carcinoma","volume":"157","author":"Eva","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.11.009_bb0035","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/PGP.0000000000000620","article-title":"HPV-independent vulvar squamous cell carcinoma is associated with significantly worse prognosis compared with HPV-associated tumors","volume":"39","author":"Allo","year":"2020","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.009_bb0040","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/his.13205","article-title":"Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study","volume":"71","author":"McAlpine","year":"2017","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.ygyno.2025.11.009_bb0045","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ygyno.2020.09.024","article-title":"Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes","volume":"159","author":"Kortekaas","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2025.11.009_bb0050","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1136\/ijgc-2022-003616","article-title":"HPV-independent and HPV-associated vulvar squamous cell carcinoma: two different cancers","volume":"32","author":"Eva","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2025.11.009_bb0055","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/PGP.0000000000000263","article-title":"p16 immunostaining allows for accurate subclassification of vulvar squamous cell carcinoma into HPV-associated and HPV-independent cases","volume":"35","author":"Cheng","year":"2016","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"24","key":"10.1016\/j.ygyno.2025.11.009_bb0060","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.3390\/cancers16244216","article-title":"Molecular subtypes of vulvar squamous cell carcinoma: the significance of HPV-independent\/p53 wild type","volume":"16","author":"Horn","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ygyno.2025.11.009_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100145","article-title":"Classification of vulvar squamous cell carcinoma and precursor lesions by p16 and p53 immunohistochemistry: considerations, caveats, and an algorithmic approach","volume":"36","author":"Yang","year":"2023","journal-title":"Mod. Pathol."},{"issue":"16","key":"10.1016\/j.ygyno.2025.11.009_bb0070","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in metastatic triple-negative breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2025.11.009_bb0075","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of Trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.11.009_bb0080","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab Vedotin as second- or third-line therapy for recurrent cervical Cancer","volume":"391","author":"Ignace","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ygyno.2025.11.009_bb0085","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.ygyno.2025.11.009_bb0090","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab Soravtansine in FR\u03b1-positive, platinum-resistant ovarian Cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ygyno.2025.11.009_bb0095","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03783-8","article-title":"CLDN18.2\u2013targeting antibody\u2013drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial","volume":"31","author":"Liu","year":"2025","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.ygyno.2025.11.009_bb0100","doi-asserted-by":"crossref","first-page":"8235","DOI":"10.1007\/s00432-023-04761-8","article-title":"TROP-2 is widely expressed in vulvar squamous cell carcinoma and represents a potential new therapeutic target","volume":"149","author":"Condic","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.11.009_bb0105","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000543554","article-title":"Trop2-expression in correlation to the molecular subtype in vulvar squamous cell carcinomas (VSCC)","volume":"92","author":"H\u00f6hn","year":"2025","journal-title":"Pathobiology"},{"key":"10.1016\/j.ygyno.2025.11.009_bb0110","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ygyno.2025.03.049","article-title":"Trop2-expression in primary vulvar squamous cell carcinoma","volume":"196","author":"Stuebs","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.009_bb0115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2022.01.029","article-title":"Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study","volume":"166","author":"Shapira-Frommer","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"31","key":"10.1016\/j.ygyno.2025.11.009_bb0120","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.19.00739","article-title":"Safety and efficacy of Nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II CheckMate 358 trial","volume":"37","author":"Naumann","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.009_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives","volume":"106","author":"Nicol\u00f2","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ygyno.2025.11.009_bb0130","article-title":"Prognostically favorable immune responses to ovarian cancer are distinguished by self-reactive intra-epithelial plasma cells","author":"Banville","year":"2025","journal-title":"bioRxiv [Preprint]"},{"key":"10.1016\/j.ygyno.2025.11.009_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2025.105926","article-title":"Assessment of Nectin4-expression in vulvar squamous cell carcinomas (VSCC): correlation with HPV-associated and HPV-independent molecular subtypes","volume":"164","author":"H\u00f6hn","year":"2025","journal-title":"Hum. Pathol."},{"issue":"04","key":"10.1016\/j.ygyno.2025.11.009_bb0140","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1055\/s-0039-1687894","article-title":"Tissue factor and Cancer: regulation, tumor growth, and metastasis","volume":"45","author":"Hisada","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"issue":"5","key":"10.1016\/j.ygyno.2025.11.009_bb0145","first-page":"4075","article-title":"Expression of tissue factor in human cervical carcinoma tissue","volume":"16","author":"Zhao","year":"2018","journal-title":"Exp. Ther. Med."},{"issue":"6","key":"10.1016\/j.ygyno.2025.11.009_bb0150","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/his.12090","article-title":"HER2 amplification in squamous cell carcinomas of the vulva","volume":"62","author":"Choschzick","year":"2013","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.ygyno.2025.11.009_bb0155","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2022.33.e82","article-title":"High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer","volume":"33","author":"Yazaki","year":"2022","journal-title":"J. Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.11.009_bb0160","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1186\/s12885-025-13940-4","article-title":"Claudin 18.2 expression profile in primary tumors and their ovarian metastases: implications for targeted therapy","volume":"25","author":"Kim","year":"2025","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2025.11.009_bb0165","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/his.15112","article-title":"PD-L1 expression in vulvar cancer: a systematic review and meta-analysis","volume":"84","author":"Baandrup","year":"2024","journal-title":"Histopathology"},{"issue":"20","key":"10.1016\/j.ygyno.2025.11.009_bb0170","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical Cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ygyno.2025.11.009_bb0175","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.3390\/cancers13205206","article-title":"The key differences between human papillomavirus-positive and-negative head and neck cancers: biological and clinical implications","volume":"13","author":"Powell","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ygyno.2025.11.009_bb0180","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13058-023-01724-2","article-title":"Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms","volume":"25","author":"Sigurjonsdottir","year":"2023","journal-title":"Breast Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582501087X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582501087X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:11:28Z","timestamp":1773810688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582501087X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"alternative-id":["S009082582501087X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.11.009","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring novel therapeutic targets in vulvar squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}